Vyndamax(Tafamidis)
PFE
Medicare prescription drug cost, prescriptions and prescribers, 2024 · made by Pfizer Inc.
$2.83B
Medicare cost, 2024
$2.83B
Medicare cost, 2024
Medicare drug plans spent $2.8 billion on Vyndamax (tafamidis) in 2024, for 109,373 prescriptions and refills filled by 13,925 patients. It ranks 16th among all drugs by Medicare drug plan spending. Spending rose 110% from 2023 to 2024. At about $25,882 per prescription it is a high-cost drug.
Medicare cost, 2024
$2.83B
+109.8% from 2023
Prescriptions
109K
$25,882.18 per claim
Patients
14K
4,416 prescribers
Total spending, 2024
$2.83B
$203,289.90 per patient
Questions and answers
How much does Medicare spend on Vyndamax?
Medicare prescription drug plans paid $2.83B for Vyndamax in 2024, for 109,373 prescriptions and refills to 13,925 patients (up 109.8% from 2023). The average cost per claim was $25,882.18.
Which state spends the most on Vyndamax?
New York had the highest Medicare cost for Vyndamax in 2024: $334.4M for 11,451 claims, followed by California ($243.2M).
Who prescribes Vyndamax the most?
Sarah Cuddy, cardiology in Boston, MA, had the highest Medicare cost for Vyndamax in 2024: 1,675 claims costing $39.5M.
Who makes Vyndamax?
Vyndamax is made by Pfizer Inc. (PFE), listed in the Medicare spending data as Pfizer US Pharm.
Spending over the years
Medicare spending by year
All plans and makers
Prescriber data: cost by year
Medicare spending on Vyndamax was $2.83B in 2024, the highest year shown.
By state
Where the prescribers practice, 2024
Medicare cost by state
States with the highest cost
Top prescribers of Vyndamax, 2024
By Medicare drug cost
| Prescriber | Type | Claims | Patients | Cost |
|---|---|---|---|---|
| Sarah Cuddy Boston, MA | Cardiology | 1,675 | 189 | $39.5M |
| Maureen C Geary New York, NY | Nurse Practitioner | 1,057 | 187 | $37.1M |
| Brian M Drachman Philadelphia, PA | Cardiology | 1,013 | 133 | $28.2M |
| Margaret O Cuomo New York, NY | Nurse Practitioner | 892 | 137 | $27.2M |
| Prem Soman Pittsburgh, PA | Cardiology | 964 | 111 | $22.5M |
| Zubair I Shah Kansas City, KS | Advanced Heart Failure and Transplant Cardiology | 958 | 110 | $21.1M |
| Kunal N Bhatt Atlanta, GA | Advanced Heart Failure and Transplant Cardiology | 755 | 92 | $18.8M |
| Mazen A Hanna Cleveland, OH | Advanced Heart Failure and Transplant Cardiology | 740 | 89 | $18.2M |
| Janice Pieretti Philadelphia, PA | Advanced Heart Failure and Transplant Cardiology | 572 | 89 | $16.8M |
| Josef Stehlik Salt Lake City, UT | Cardiology | 725 | 76 | $16.7M |
| Sabeena Arora Hartford, CT | Cardiology | 537 | 94 | $16.5M |
| Ronald M Witteles Stanford, CA | Cardiology | 621 | 64 | $14.6M |
| Ahmad M Masri Portland, OR | Cardiology | 548 | 70 | $14.2M |
| Brett W Sperry Kansas City, MO | Advanced Heart Failure and Transplant Cardiology | 611 | 71 | $14.1M |
| Hanna K Gaggin Boston, MA | Cardiology | 581 | 71 | $13.5M |
| Edward J Miller New Haven, CT | Cardiology | 518 | 68 | $13.4M |
| Rebecca R Hung Nashville, TN | Cardiology | 531 | 63 | $13.2M |
| Joban Vaishnav Baltimore, MD | Cardiology | 391 | 65 | $12.7M |
| Elsy V Navas Naples, FL | Advanced Heart Failure and Transplant Cardiology | 429 | 61 | $11.9M |
| Kaylee M Baker Philadelphia, PA | Nurse Practitioner | 432 | 60 | $11.8M |
| David L Stern Great Neck, NY | Cardiology | 404 | 59 | $11.6M |
| Richard K Cheng Seattle, WA | Advanced Heart Failure and Transplant Cardiology | 401 | 47 | $11.3M |
| Cesia Maria Gallegos Kattan New Haven, CT | Cardiology | 401 | 53 | $11.2M |
| Omar K Siddiqi Boston, MA | Cardiology | 462 | 48 | $11.1M |
| Brendan J Carry Danville, PA | Internal Medicine | 493 | 55 | $10.7M |
Prescriber data by year
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 2,100 | 34,843 | 5,087 | $845.0M |
| 2023 | 2,926 | 52,367 | 7,586 | $1.35B |
| 2024 | 4,416 | 109,373 | 13,925 | $2.83B |
Makers, 2024
Spending by manufacturer as listed in the spending data
| Manufacturer | Claims | Spending |
|---|---|---|
| Pfizer US Pharm | 109,373 | $2.83B |
Medicaid spending by quarter
Amount reimbursed by state Medicaid programs, all states
Amount reimbursed
Codes
- National drug codes (packages)
- 1
- RxNorm concept IDs
- 2168534, 2168540, 2168542, 2168548
- Application numbers
- NDA212161
More drugs: Medicare drug spending and the Prescriptions view.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
Through September 2026, 12,176 side-effect reports named tafamidis, the active ingredient of Vyndamax (reports from 2015 on). 9,441 of them (77.5%) were serious, 4,214 named a death and 3,429 named a hospital stay. The reactions named most often were death, dyspnoea and off label use. 10,357 reports came in the last 5 years (since 2022).
How to read these numbers
- A report shows that a patient, doctor or drug company suspected a link. It does not prove that the drug caused the effect.
- Counts are not risk rates. They depend on how many people use the drug, how long it has been sold, news and reporting habits, so they do not show which drug is safer.
- The newest months are partial: reports keep arriving late.
Reports, all years
12,176
2,110 in 2025 (-17.1% from 2024)
Serious
77.5%
9,441 reports
Deaths named
4,214
34.6% of reports
Hospital stays
3,429
28.2% of reports
Reports by year
Serious reports include those that name a death, a hospital stay, a disability or another serious outcome.
Reports received by year
2026 is the year so far.
Reports naming a death or a hospital stay
One report can name both
Reactions
Reactions named most often
All years. Share = part of all reports in that period. A report can name several reactions.
Patients
As given in the reports; many reports leave sex or age out.
Sex of the patient
All years
Age of the patient
Age when the effect started, all years
Questions and answers
How many side-effect reports name Vyndamax?
12,176 reports from 2015 through September 2026 named tafamidis, the active ingredient of Vyndamax. 9,441 of them (77.5%) were serious, 4,214 named a death and 3,429 named a hospital stay.
What are the most reported side effects of Vyndamax?
3,266 reports named death, the reaction named most often, followed by dyspnoea (804) and off label use (661). In the last 5 years the reaction named most often was death (2,717 reports). A report can name several reactions.
How many side-effect reports named Vyndamax in 2025?
2,110 reports were received in 2025 (-17.1% from 2024). 2026 so far: 1,447 reports through September 2026, and more keep arriving late.
Do side-effect reports prove that Vyndamax caused a problem?
No. A report shows that a patient, doctor or drug company suspected a link; it does not prove that Vyndamax caused the effect. Report counts depend on how widely a drug is used, how long it has been sold, news and reporting habits, so they are not risk rates and do not show which drug is safer.
Related pages
- Makers on the stock market:
PFE·PFE drug pipeline - Drug approvals (1 approval on file for tafamidis) · Clinical trials · Medicare drug spending
Side-effect reports from official public data, counted per active ingredient (tafamidis) by the year the report was received, so the brand and generic pages of one ingredient show the same reports. A report can name several drugs and several reactions and counts for each. Reaction names are the standard medical terms used in the reports. Reports whose product could not be matched to a drug are not counted. Updated November 2026.